Medtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe
Medtronic Announces CE Mark of Evolut™ PRO+ TAVI System for Treatment of Symptomatic Severe Aortic Stenosis Patients in Europe News provided by Share this article Share this article As TAVI Patient Population Grows, PRO+ TAVI System Launches with Four Valve Sizes and Lowest Delivery Profile DUBLIN, May 3, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced CE (Conformité Européenne) Mark of the Evolut™ PRO+ TAVI System – the newest-generation Medtronic TAVI system that builds off the proven self-expanding, supra-annular Evolut TAVI...
Source: prnewswire.com